• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Laidlaw initiated coverage on Nuvectis Pharma with a new price target

    3/17/25 7:40:44 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00
    Get the next $NVCT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

      Drug-drug interaction ("DDI") clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor receptor ("EGFR") and anaplastic lymphoma kinase ("ALK") inhibitors for the treatment of non-small cell lung cancer ("NSCLC") are substrates of the Cytochrome P450 ("CYP") enzyme CYP3A, and therefore their combination with drugs that are strong inducers of CYP3A is to be avoided, or is contraindicated.As per the International Council for Harmonization ("ICH") M12, topline results from the NXP900 DDI clinical study classify NXP900 as a weak inhibitor

      7/8/25 8:00:00 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

      Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor ConferenceDateMay 20th, 2025Time10:30 – 11:00 a.m. ETLinkNuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on

      5/16/25 4:35:00 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod

      5/6/25 8:00:11 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    SEC Filings

    See more
    • Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

      6/13/25 5:00:08 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:20:51 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nuvectis Pharma Inc.

      424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:12:42 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/24/25 5:14:35 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/20/25 9:50:29 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kaplan Matthew L. was granted 30,000 shares, increasing direct ownership by 36% to 113,760 units (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/12/25 4:31:16 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/24/25 5:14:35 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/20/25 9:50:29 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $171,664 worth of shares (21,167 units at $8.11) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/13/25 6:36:36 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Nuvectis Pharma with a new price target

      Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

      4/2/25 8:05:05 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw initiated coverage on Nuvectis Pharma with a new price target

      Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

      3/17/25 7:40:44 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

      Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

      7/13/22 8:35:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      11/5/24 10:55:09 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/28/24 8:37:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nuvectis Pharma Inc.

      SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/6/24 8:47:33 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care